IP Library › Granted Patent US 12,138,471
Granted Patent B2
US 12,138,471 · App. 17/309,538 · Granted Nov 12, 2024

Methods for treating disorders and for stimulating stem cells by administering light therapy

Inventors: Peter Robert Brawn (Vancouver, CA); Ke Shyang See (George Town, MY)
Assignee: Biolux Group SA
A61N5/0613A61N5/0603A61N5/0616A61N5/0618A61N2005/0606A61N2005/0659A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,138,471
App. No.
17/309,538
Granted
Nov 12, 2024
Kind
B2
Abstract

The disclosure relates generally to methods for treating or slowing progression of a tumor, a neurodegenerative disease or a cognitive impairment, and for improving cognition, comprising administration of light therapy. The disclosure also relates to methods for activating oral stem cells, comprising administration of light therapy. Further provided herein are methods for improving cognition, comprising administering to the oral cavity of a subject in need thereof an effective amount of light. Additionally provided herein are methods for treating autism or Asperger's syndrome, comprising administering to the oral cavity of a subject in need thereof an effective amount of light.

Claims (22)

1. A method for preferentially activating oral stem cells, comprising:

positioning an intra-oral device within the oral cavity of a subject; and

intra-orally administering a first effective amount of light at a first wavelength to a first selected region of the oral cavity of the subject; and

intra-orally administering a second effective amount of light at a second wavelength to a second selected region of the oral cavity in need thereof such that a directional migration of the oral stem cells into blood vessels is enhanced and the oral cavity is differentially treated, wherein the first wavelength is different from the second wavelength and the first selected region is different from the second selected region of the oral cavity.

2. The method of claim 1 , wherein intra-orally administering the first effective amount of light proliferates or differentiates the oral stem cells.

3. The method of claim 1 , wherein the oral stem cells are adult stem cells.

4. The method of claim 1 , wherein the oral stem cells are mesenchymal stem cells.

5. The method of claim 1 wherein the oral stem cells are dental stem cells or non-dental stem cells.

6. The method of claim 1 , wherein the oral stem cells are dental pulp stem cells, stem cells of the apical papilla, periodontal ligament stem cells, dental follicle stem cells, tooth germ progenitor cells, oral epithelial stem cells, gingival-derived mesenchymal stem cells, inflamed periapical progenitor cells, periosteal stem cells, jaw bone marrow stem cells, alveolar bone marrow mesenchymal stem cells or salivary gland stem cells.

7. The method of claim 1 , wherein the oral stem cells are inside a mouth of the subject.

8. The method of claim 1 , wherein the oral stem cells are in a bone marrow of the subject's maxilla and/or mandible.

9. The method of claim 1 , wherein the oral stem cells are not cancer stem cells.

10. The method of claim 1 , wherein the administering the first effective amount of light comprises irradiating the light directly to the subject's alveolar mucosa, buccal mucosa, labial mucosa, masticatory mucosa, tooth, gum or tongue.

11. The method of claim 1 , wherein the first effective amount of light has a wavelength ranging from about 600 nm to about 1,200 nm.

12. The method of claim 1 , wherein the first effective amount of light has a power density ranging from about 20 mW/cm 2 to about 200 mW/cm 2 .

13. The method of claim 1 , wherein the first effective amount of light has an energy density ranging from about 5 J/cm 2 to about 50 J/cm 2 .

14. The method of claim 1 , further comprising extra-orally administering the first effective amount of light.

15. The method of claim 14 , wherein the extra-orally administering is by an extra-oral device.

16. The method of claim 1 , wherein the first effective amount of light is a first light and wherein the second effective amount of light is a second light administered to the subject's skin.

17. The method of claim 16 , wherein the skin is the skin of the subject's scalp, face or neck.

18. The method of claim 16 , wherein the second light is administered extra-orally to the subject's skin.

19. The method of claim 18 , wherein the second light is administered extra-orally by an extra-oral device.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2024
From: LLLT TECHNOLOGIES SA
To: BIOLUX GROUP SA
Reel/Frame 068219/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2023
From: BIOLUX RESEARCH LIMITED
To: BIOLUX RESEARCH HOLDINGS, INC.
Reel/Frame 064002/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: SEE, KE SHYANG
To: OSEI INTERNATIONAL SDN BHD.
Reel/Frame 062333/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: OSEL INTERNATIONAL SDN BHD.
To: BIOLUX RESEARCH LTD.
Reel/Frame 062333/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: BIOLUX (ABC), LLC
To: LLLT TECHNOLOGIES SA
Reel/Frame 062333/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: BIOLUX RESEARCH HOLDINGS, INC.
To: BIOLUX (ABC), LLC
Reel/Frame 062333/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2023
From: BRAWN, PETER
To: QUINCAMPOIX INVESTMENT CORPORATION
Reel/Frame 062333/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2022
From: QUINCAMPOIX INVESTMENT CORPORATION
To: LLLT TECHNOLOGIES SA
Reel/Frame 061811/0444 →
Continuity (2)
Provisional Application 62779615 · Dec 14, 2018
Related Publication 20220118274A1 · Apr 21, 2022